Group items tagged

The General Pharmaceutical Council (GPhC) has strongly condemned recent acts of racism, violence, and disorder caused by far-right, anti-immigrant protestors across the UK. Roz Gittins, chief pharmacy officer at GPhC, expressed deep concern for the safety of pharmacy teams, particularly those from Black and minority ethnic backgrounds. He said: "We strongly condemn the racism, violence and disorder caused by a small minority of the population that has taken place over recent days." "We understand that pharmacy teams serving our communities may feel especially vulnerable at this time." "Pharmacists and pharmacy technicians from black and minority ethnic backgrounds, as well as those who trained abroad, make an enormous contribution to our pharmacy and health services and they should never have to feel fear when going to work.

The Pharmacists' Defence Association (PDA) has reported growing concerns among its members regarding their safety at work as the far-right, anti-immigration riots escalate across the UK. "We have received calls from members who are concerned about their safety at work and feel vulnerable in communities where the violence and disorder are taking place," the organisation told Pharmacy Business. The PDA also reported that some hospital outpatient departments and GP surgeries were forced to close their doors to allow staff to get home safely, which may impact services to patients. In light of these challenges, the PDA is calling on employers to ensure that they are adequately communicating with pharmacists in locations at risk of conflict and to prioritise the health and safety of staff and patients. "We are aware that pharmacists and their teams working in areas where this criminal activity is taking place are feeling vulnerable but that they also want to ensure that their communities are safe and have access to the vital services pharmacies provide.

The Pharmacists' Defence Association (PDA) has written to the National Pharmacy Association (NPA) to highlight several important points regarding their proposed "day of action" on 20 June 2024. The NPA describes this initiative as a response to the "emergency across the community pharmacy sector." In a letter addressed to NPA Chair Nick Kaye and Chief Executive Paul Rees, the PDA's director of pharmacy, Jay Badenhorst stressed the need for NPA members to consider their obligations to staff and patients before participating in the planned actions. He stated, "We are supportive of a new contractual framework for the community pharmacy sector." "However, any actions taken must ensure the safety of patients and the operational integrity of pharmacies." The PDA's letter also expressed concerns over the safety and operational impact of the proposed symbolic gestures, including turning off lights and blacking out windows.

The Royal Pharmaceutical Society (RPS) presented key evidence to the UK COVID-19 Inquiry on 10 September, underscoring the vital role of pharmacists and pharmacy teams during the pandemic. Deirdre Domingo, legal representative for the RPS, delivered the statement during the Module 3 public hearings, which focus on the impact of COVID-19 on healthcare systems across the UK. As the professional body representing pharmacists and pharmaceutical scientists in Great Britain, the RPS urged the Inquiry to consider several critical issues: Recognition of pharmacists as key workers The RPS highlighted the crucial role pharmacy teams played in ensuring continued access to essential medicines and their integral involvement in the roll-out of COVID-19 and flu vaccinations. However, the Society also raised concerns over significant failures and challenges, such as inadequate safety measures to protect pharmacists at work, confusing national guidance, increased hostility towards healthcare professionals, and a disparity in the treatment of community pharmacy compared to NHS staff.

Community Pharmacy Scotland (CPS), along with 47 public and voluntary sector organisations, has endorsed a letter to UK Chancellor Rachel Reeves, seeking funding support for employer national insurance contributions ahead of the planned increases from the 1st of April 2025. The letter, co-signed by first minister John Swinney and COSLA president Shona Morrison, raises concerns over the impact of the impending increase, which is estimated to cost public service providers in Scotland over £700 million. The Scottish Government calculated that the policy's cost for the directly employed public sector could be around £550 million, with councils accounting for about £265 million of that total. If contractors and commissioned services are included, the total costs could exceed £700 million. The letter also underscores the significant impact on charitable organisations, stating that "there is a real risk that these costs will see employers unable to award meaningful pay rises, retain staff or even continue to operate." The Scottish Council for Voluntary Organisations has estimated that the Third Sector, comprising charities, social enterprises and grassroot community groups, will face additional costs of £75 million per year, plus wider inflation.

Professor Anthony Harnden has officially commenced his role as chair of the Medicines and Healthcare products Regulatory Agency (MHRA). During his first 100 days, Professor Harnden plans to engage extensively with MHRA staff and partner organisations to gain a strong understanding of "how to drive forward the strategic direction of the MHRA to maintain the UK as a global centre of excellence in life sciences, in the best interests of patients and the public." The new MHRA chair has highlighted three primary areas of focus: Protect patient safety through robust safety surveillance systems Embrace risk-proportionate regulation Foster an inclusive workplace where people flourish. With a 40-year career in the NHS, including 33 years as a general practitioner in Wheatley, Oxfordshire, Professor Harnden brings a wealth of experience to the role. He is a professor of primary care at the University of Oxford. Until December 2024, he was also a registrant council member of the General Medical Council and chair of the Remuneration Committee.